Table 1 Clinical characteristics of patients with invasive aspergillosis at the time of IA diagnosis
|  | Period 1a (n = 15) | Period 2b (n = 14) |
|---|---|---|
Age, median years (IQR) | 44 (17–60) | 59 (43–63) |
Male gender, no. (%) | 10 (59) | 11 (73) |
Underlying hematologic disease, no. (%) | ||
 Acute myeloid leukemia | 8 (47) | 5 (33) |
 Acute lymphoid leukemia | 1 (6) | 2 (13) |
 Myelodysplastic syndrome | 3 (18) | 0 (0) |
 Lymphoma | 2 (12) | 1 (7) |
 Othersc | 3 (18) | 7 (47) |
Immunocompromised condition | ||
 Neutropeniad | 12 (80) | 11 (79) |
 Hematopoietic stem cell transplant | 6 (40) | 5 (36) |
 Steroid usee | 3 (20) | 3 (21) |
 T-cell immunosuppressant | 2 (13) | 3 (21) |
 Human immunodeficiency virus infection | 1/15f (7) | 0/12f (0) |
Symptoms at the time of IA diagnosis | ||
 Fever | 13 (87) | 11 (79) |
 Cough | 4 (27) | 4 (29) |
 Sputum | 2 (13) | 4 (29) |
 Dyspnea | 6 (40) | 3 (21) |
Positive results for serum galactomannan | 9 (53) | 12 (80) |
Positive results for beta-D-glucan | 8/14f (57) | 9/12f (75) |
Positive results for culture specimens | 4 (24) | 4 (27) |
Hospitalization days before IA diagnosis, median days (IQR) | 23.0 (9.0–58.0) | 43.5 (12.8–86.3) |
Antifungal prophylaxis | ||
 Micafungin | 2 (13) | 1 (7) |
 Posaconazole | 1 (7) | 2 (14) |
 Fluconazole | 2 (13) | 2 (14) |
 No antifungal prophylaxis | 10 (67) | 9 (64) |
Antifungal agentg | ||
 Voriconazole | 11 (65) | 11 (73) |
 Amphotericin B | 5 (29) | 1 (7) |
 Echinocandin | 1 (6) | 1 (7) |
 Others | 0 (0) | 2 (13) |
 30-day mortality | 5 (29) | 3 (20) |